The Latest Breaking News from Biogen

Lecanemab is the first drug to help improve the symptoms of Alzheimer’s by slowing the disease. These are very promising results, although the only data we have at the moment is from the drugmaker’s press release.

According to drugmakers Eisai and Biogen, a Phase 3 clinical study on a potential new Alzheimer's disease drug shows promise. The study findings show that the drug, lecanemab, reduced clinical decline of people with Alzheimer's disease by 27% compared with a placebo after 18 months of treatment.

Volatility expected to remain heightened (in ‘both directions’) until the Fed manages to get inflation back under control.

But positive clinical trial results also renew the hopes of millions of seniors.

Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial met its primary endpoint.

U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session.

Dow Jones futures fell as Treasury yields rebounded, signaling Wednesday's rally may be short-lived. Eli Lilly leads some bullish stocks.

Eli Lilly And Co (NYSE:LLY) - Market cap: $295 billion.

The Dow Jones powered higher. A Cathie Wood buy was surging as Biogen exploded. Coinbase stock jumped as Bitcoin rose. Apple stock dived.